Screening for Hepatocellular Carcinoma and Cholangiocarcinoma: Can Biomarkers Replace Imaging?

Lozada, María E.; Chaiteerakij, Roongruedee; Roberts, Lewis R.

doi:10.1007/s11901-015-0261-y

Cited by 8 publications

(8 citation statements)

References 86 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dickkopf-1 (DKK1) is a glycoprotein that is a secretory antagonist of the Wnt/B-catenin signaling pathway [52]. Its exact function is not fully understood but upregulation of DKK1 expression occurs in a wide variety of cancers, including multiple myeloma, prostate cancer and HCC [53].…”

Section: Dickkopf-1mentioning

confidence: 99%

Biomarker development for hepatocellular carcinoma early detection: current and future perspectives

Sengupta

Parikh

2017

Hepat. Oncol.

View full text Add to dashboard Cite

Early detection of hepatocellular carcinoma (HCC) leads to improved survival; however, current early detection strategies for HCC surveillance are ineffective. Thus, there has been interest in developing biomarkers to aid in the early detection HCC. In this review, we discuss the five phases of biomarker discovery that are necessary for clinical implementation. We also describe the most promising investigational biomarkers and their phase of discovery. We review several promising technologies for the early detection of HCC, including miRNA, metabolomics and proteomics. Promisingly, there are samples from multiple longitudinal cohorts of patients with cirrhosis in the USA that are being collected in order to validate candidate biomarkers for HCC. A biomarker-based strategy has the potential to become the primary surveillance method for HCC detection.

show abstract

Section: Dickkopf-1mentioning

confidence: 99%

Biomarker development for hepatocellular carcinoma early detection: current and future perspectives

Sengupta

Parikh

2017

Hepat. Oncol.

View full text Add to dashboard Cite

show abstract

“…Chronic biliary tract inflammation due to liver fluke [ Opisthorchis viverrini (OV)] infection together with exposure to carcinogens associated with poor hygiene is the most common risk factor for CCA in the endemic areas (1). At present, the prognosis of patients with CCA is generally poor due to lack of early detection (2). Accurate surveillance guidelines (used to detect the presence of CCA) for healthy individuals or patients with benign biliary diseases are yet to be determined (2).…”

Section: Introductionmentioning

confidence: 99%

Serum coiled‑coil domain containing 25 protein as a potential screening/diagnostic biomarker for cholangiocarcinoma

et al. 2019

View full text Add to dashboard Cite

Coiled-coil domain containing 25 (CCDC25) was previously reported to be upregulated in cholangiocarcinoma (CCA) tissues compared with adjacent normal tissues. The present study investigated whether serum CCDC25 level may be used as a potential marker for the diagnosis of CCA. Bioinformatics tools were used to reveal that CCDC25 is secreted into plasma/serum via a non-conventional pathway, which secretes proteins independently from the endoplasmic reticulum/golgi complex, but is yet to be fully elucidated. Subsequently, the CCDC25 levels in the sera of patients with CCA (n=141), patients with benign biliary disease (BBD; n=53) and healthy controls (HC; n=72) were measured using a quantitative dot blot assay based on the standard curve created using recombinant CCDC25 protein. The results demonstrated that the serum CCDC25 level in the CCA group (0.28±0.06 ng/µl) was significantly higher compared with that in the BBD (0.15±0.03 ng/µl) or HC (0.0017±0.0008 ng/µl) groups. Serum CCDC25 level provided an improved resolution (P=0.0001) compared with carcinoembryonic antigen (P=0.098) or carbohydrate antigen 19-9 (P=0.271) for the differential diagnosis between BBD and CCA. Receiver operating characteristic curve analysis revealed high sensitivity and specificity of serum CCDC25 level to differentiate between patients with CCA and HC (93.0 and 100%, respectively), and also to differentiate between patients with CCA and patients with BBD (75.0 and 84.0%, respectively). CCDC25 expression was further investigated in 23 CCA tissues, and CCDC25 expression in cancer tissues was moderately correlated with the serum CCDC25 level (r 2 =0.52, P=0.01). Among patients with CCA, serum CCDC25 level was significantly higher in patients with non-metastatic CCA compared with patients with metastatic CCA. Correspondingly, a higher serum CCDC25 level was associated with a longer overall survival time in patients with CCA. In conclusion, serum CCDC25 level may be a promising screening and diagnostic marker for the differential diagnosis of CCA.

show abstract

“…If biliary dominant strictures are present, regular ERCP with brush cytology is recommended. This is not ideal for surveillance; it is invasive, costly, and has low diagnostic accuracy 51. Solely screening for CCA might not be feasible.…”

Section: Screening Strategiesmentioning

confidence: 99%

“…To overcome this limitation, it is proposed to design a multicancer detection panel that combines CCA markers with other markers of uncommon respiratory and digestive tract cancers or aerodigestive cancers. This screening modality may justify and permit CCA screening in countries with low incidence 51…”

Section: Screening Strategiesmentioning

confidence: 99%

Cholangiocarcinoma: a guide for the nonspecialist

Alsaleh¹,

Leftley²,

Barbera³

et al. 2018

IJGM

View full text Add to dashboard Cite

Cholangiocarcinoma (CCA) is a tumor with increasing prevalence around the world. The prevalence of CCA is highest in East Asia and most significantly in the countries through which the Mekong River flows, owing to the presence of liver flukes, which are consumed in raw fish dishes. Outside Asia, the causes of bile duct cancers for the most part are unknown. In this review, we assess the current state of knowledge in both fluke-associated and sporadic CCA, from etiological, diagnostic, and treatment perspectives.

show abstract

Screening for Hepatocellular Carcinoma and Cholangiocarcinoma: Can Biomarkers Replace Imaging?

Cited by 8 publications

References 86 publications

Biomarker development for hepatocellular carcinoma early detection: current and future perspectives

Biomarker development for hepatocellular carcinoma early detection: current and future perspectives

Serum coiled‑coil domain containing 25 protein as a potential screening/diagnostic biomarker for cholangiocarcinoma

Cholangiocarcinoma: a guide for the nonspecialist

Contact Info

Product

Resources

About